Oral mucositis

What it is

Oral mucositis is painful inflammation and ulceration of the mouth lining during cancer treatment, affecting about 40% of chemotherapy patients. It is a common side effect of chemotherapy, radiotherapy to the head and neck, or combined chemoradiation. The mouth lining first becomes red and sore, then may develop shallow or larger ulcers that make eating, drinking, swallowing, speaking, and oral hygiene difficult.

This is not just a minor mouth problem. Oral mucositis can lead to dehydration, poor nutrition, infection risk, hospital admission, opioid pain use, and delays or dose reductions in cancer treatment. Risk is especially high with high-dose chemotherapy before stem cell transplant, where clinically significant oral mucositis has been reported in about 75% to 80% of patients, and with head and neck chemoradiation, where severe mucositis is common.

Typical timing depends on treatment type. With chemotherapy, visible changes often begin around 4 to 5 days after treatment starts, and ulcers may appear by 7 to 10 days. With radiation to the oral cavity, symptoms usually build gradually over the course of treatment.

How it works

Cancer treatment damages rapidly dividing basal cells in the oral mucosa. That direct injury sets off a chain of biological events involving reactive oxygen species, inflammatory signaling, and breakdown of the protective mucosal barrier. As the lining thins and breaks, painful erosions and ulcers form.

The process is often described in stages:

1. Initial injury: chemotherapy or radiation damages mucosal cells and DNA.
2. Inflammatory signaling: cytokines and pathways such as NF-kappaB amplify tissue injury.
3. Ulceration: the surface breaks down, exposing nerve endings and allowing oral bacteria to colonise damaged tissue.
4. Healing: once treatment intensity falls and cells recover, the mucosa gradually re-epithelialises.

Chemotherapy-related lesions often affect non-keratinised surfaces such as the inner cheeks, soft palate, floor of mouth, and sides or underside of the tongue. Radiation-related mucositis usually occurs in the areas included in the radiation field.

Evidence and uses

The main goals are prevention when possible, early recognition, pain control, infection prevention, and support for nutrition and hydration. Management is usually tailored to the cancer treatment being given.

A short comparison is helpful:

Situation	What is commonly used	What evidence suggests
Standard supportive care	Frequent oral care, bland rinses, hydration, dental review	Widely recommended and low risk; helps comfort and hygiene
Short-infusion chemotherapy such as 5-FU or high-dose melphalan	Oral cryotherapy with ice chips during drug infusion	Supported for selected regimens because cooling reduces blood flow to oral tissues
Head and neck radiotherapy or chemoradiotherapy	Protocol-based oral care; in some settings benzydamine or photobiomodulation/low-level laser therapy	Evidence supports benefit in selected patients, but access and protocols vary
High-risk transplant settings	Intensive oral care; sometimes palifermin in selected protocols	Palifermin has evidence in some high-risk settings, not for every patient
Established painful ulcers	Topical anesthetic approaches, systemic pain relief, nutrition support	Helps symptoms, but no single treatment works for all cases

Supportive oral care is the foundation. This usually includes a soft toothbrush, regular mouth rinsing with bland solutions such as saline or sodium bicarbonate, lip care, avoiding tobacco and alcohol, and prompt treatment of oral infections. A dental assessment before head and neck radiation or intensive chemotherapy can reduce avoidable oral problems.

Oral cryotherapy means holding ice chips in the mouth during certain chemotherapy infusions. It has evidence for short half-life drugs such as bolus 5-fluorouracil and high-dose melphalan, where cooling may reduce drug delivery to the oral mucosa.

Palifermin, a keratinocyte growth factor, can reduce severe oral mucositis in some high-risk settings, especially around haematopoietic stem cell transplantation and in selected treatment protocols. It is not routinely used for every cancer patient and should only be used under oncology guidance.

Low-level laser therapy, now often called photobiomodulation, has shown preventive benefit in some trials and systematic reviews, especially in head and neck cancer and transplant settings. However, availability, equipment, and protocol standardisation differ across centres, including in India.

Some other approaches have mixed or limited evidence. Chlorhexidine has not shown consistent benefit for preventing treatment-related oral mucositis across settings. Evidence for glutamine, honey, zinc compounds, rebamipide, omega-3 fatty acids, and other agents is still evolving and is not strong enough to support universal use. Patients should be cautious with over-the-counter products marketed for "mouth sores," especially during active cancer treatment.

Diagnosis / how it's measured

Diagnosis is usually clinical. An oncologist, radiation oncologist, dentist, or oncology nurse examines the mouth and asks about pain, swallowing, oral intake, and bleeding.

Common features include:

• redness of the oral mucosa
• swelling
• white or yellow pseudomembranes over ulcers
• pain or burning
• difficulty eating, drinking, or swallowing
• reduced oral intake

Severity may be graded using standard scales. Two commonly used tools are:

Scale	What it measures
WHO oral toxicity scale	Combines visible changes with ability to eat solids or liquids
OMAS (Oral Mucositis Assessment Scale)	Scores erythema and ulceration at multiple oral sites

Clinicians also look for related problems that can worsen symptoms or mimic mucositis, such as oral thrush, herpes simplex infection, dehydration, neutropenia, poorly fitting dentures, or sharp teeth.

When to see a clinician

Tell your cancer team early if your mouth feels sore, even before ulcers appear. Early action can reduce pain and help you keep eating and drinking.

Seek urgent medical advice if you have any of the following:

• you cannot drink enough fluids
• severe pain stops you from eating or swallowing medicines
• fever, chills, or signs of infection
• bleeding from mouth ulcers
• white patches suggesting thrush
• rapid weight loss or dizziness from poor intake

This matters even more if you have low white blood cells. In neutropenic patients, mouth ulcers can become an entry point for serious infection.

For patients in India, practical steps such as carrying a written list of prescribed mouth rinses, checking whether your cancer centre has a mucositis protocol, and asking for dietitian input can be useful, especially during chemoradiation for head and neck cancer where oral intake often falls quickly.

Limitations and open questions

Oral mucositis is common, but prevention and treatment are still imperfect. Risk varies a lot by chemotherapy drug, radiation field and dose, combined treatment, oral health, age, and transplant status. That means a strategy that helps one patient may not help another.

Evidence is strongest for a few interventions in specific settings, not for all cancers or all regimens. Many studies are small, use different grading scales, or test combinations of supportive measures, making direct comparison difficult. Newer approaches such as photobiomodulation and selected protective agents are promising, but access, cost, and standardisation remain issues.

There is also no reliable way to completely prevent oral mucositis in every patient. If you are starting chemotherapy or head and neck radiation, ask your oncology team what your personal risk is, what preventive plan they use, and which symptoms should trigger a same-day call.